STOCK TITAN

Atossa Therapeutics Inc - ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Atossa Therapeutics Inc (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company pioneering novel therapies for breast cancer and breast health conditions. This page provides investors and healthcare stakeholders with comprehensive access to official press releases, clinical trial developments, and regulatory updates directly from the company.

Track progress on key initiatives including (Z)-endoxifen clinical trials, innovative drug delivery systems like intraductal microcatheter technology, and strategic partnerships. Our curated news collection ensures timely updates on FDA communications, research milestones, and intellectual property developments relevant to oncology therapeutics.

Discover updates across three primary categories: clinical research advancements in estrogen receptor-targeted treatments, regulatory filings for breast cancer therapies, and scientific collaborations enhancing drug delivery platforms. Each update is sourced from verified company communications to maintain accuracy and compliance.

Bookmark this page for streamlined access to Atossa's latest developments in selective estrogen receptor modulation and precision medicine. Regularly updated to serve as your primary resource for understanding the company's progress in addressing unmet needs in oncology care.

Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) to provide business update and report financial results for the second quarter 2023 on August 14, 2023. Conference call to review results at 9:00 a.m. ET / 6:00 a.m. PT. Interested participants should register in advance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
-
Rhea-AI Summary
Atossa Therapeutics has received a 'No Objection Letter' from Health Canada for its Phase 2 EVANGELINE study, allowing the company to open sites and enroll patients in Canada. The study is evaluating the efficacy of Atossa's (Z)-endoxifen compared to the current standard of care for pre-menopausal women with breast cancer. The company expects enrollment to increase once the optimal dose is confirmed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
-
Rhea-AI Summary
Atossa Therapeutics regains compliance with Nasdaq's minimum bid price listing requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
none
-
Rhea-AI Summary
Atossa Therapeutics announces enrollment of 170 patients in Phase 2 Karisma-Endoxifen clinical trial for breast cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.87%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, a biopharmaceutical company focused on breast cancer, announces a share repurchase program of up to $10 million. The program reflects confidence in the company's strategic priorities and long-term prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
buyback
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
Atossa Therapeutics Inc

Nasdaq:ATOS

ATOS Rankings

ATOS Stock Data

80.49M
129.09M
0.06%
28.55%
7.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE